Published in Clinical Trials Week, September 25th, 2006
One patient from Phase II continued to be treated for 26 weeks. A cholangiocarcinoma patient from the Phase I trial was treated for more than 56 weeks. The results of these studies compare very well and exceed results from similar recent studies in the same patient populations.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.